Cas:25372-03-6 4-(1H-imidazol-1-yl)benzonitrile manufacturer & supplier

Chemical Name:4-(1H-imidazol-1-yl)benzonitrile

CAS.NO:25372-03-6

Synonyms:MFCD00127147;1-(4-cyanophenyl)-1H-imidazole;4-(1-Imidazolyl)benzonitrile;1-(4-Cyanophenyl)imidazole;4-(1H-imidazol-1-yl)-benzonitrile;4-(imidazole-1-yl)benzonitrile;Benzonitrile, p-imidazol-1-yl-;4-(1H-Imidazol-1-yl)benzonitrile;4-imidazolylbenzenecarbonitrile;Benzonitrile, 4-(1H-imidazol-1-yl)-;p-imidazol-1-ylbenzonitrile;4-(1H-imidazole-1-yl)benzonitrile;4-Imidazol-1-yl-benzonitrile

Molecular Formula:C₁₀H₇N₃

Molecular Weight:169.183

HS Code:

Physical and Chemical Properties:

Melting point:151-153 °C

Boiling point:358.1±25.0 °C at 760 mmHg

Density:1.1±0.1 g/cm3

Index of Refraction:1.623

PSA:41.61000

Exact Mass:169.063995

LogP:1.42

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:3276

Packing Group:

Contact us for information like MFCD00127147 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,4-Imidazol-1-yl-benzonitrile physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,Benzonitrile, 4-(1H-imidazol-1-yl)- Use and application,1-(4-Cyanophenyl)imidazole technical grade,usp/ep/jp grade.

Related News: In recent years, China’s bulk drug companies have gradually completed the upgrade of the product structure of bulk raw materials to specialty raw materials and intermediates. The industry’s leading companies have further developed the research and development layout of high-barrier generic pharmaceutical raw materials with multiple patents that have not yet expired. 4-(1H-imidazol-1-yl)benzonitrile manufacturer From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. 4-(1H-imidazol-1-yl)benzonitrile supplier From the three-month point onward, 84.5% of uMRD patients maintained that deep remission in the blood to the 12-month assessment. These data show the new combo can deliver “very durable remissions” for the vast majority of patients, Tendler said. 4-(1H-imidazol-1-yl)benzonitrile vendor Currently allowed as a second-line treatment, Sarclisa is expected to have top-line data from the phase 3 IMROZ trial later this year. The trial is adding Sarclisa to a VRd cocktail of Velcade, Revlimid and dexamethasone, which has established itself as the standard-of-care first-line therapy for patients with myeloma. 4-(1H-imidazol-1-yl)benzonitrile factory International Chemical Investors Group (ICIG) recently announced it has entered into a purchase agreement under which an affiliate of ICIG will acquire the pharmaceutical intermediates business from Genzyme Corporation.